Lutetium Lu 177 Dotatate Patent Expiration

1. Lutathera patent expiration

LUTATHERA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US11904027 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US10596278

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)

US10596276

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)

US11904027

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 26, 2023
Orphan Drug Exclusivity(ODE-166) Jan 26, 2025
Orphan Drug Exclusivity(ODE-479) Apr 23, 2031
Pediatric Exclusivity(PED) Oct 23, 2031

NCE-1 date: 23 October, 2030

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LUTATHERA family patents

Family Patents